Both PD‐1 and PD‐L2 were significantly upregulated in high-risk group (Figures 6A,B), suggesting the potential role of the TRLs signature in stratifying CRC patients for immune checkpoint inhibitor therapy. The gene discussed is PDCD1LG2; the disease is colorectal carcinoma.